Anglikang Pharmaceutical Receives NMPA Clinical Clearance for ALK-N001 in Advanced Solid Tumors
China-based Zhejiang Anglikang Pharmaceutical Co., Ltd (SHE: 002940) announced that it has received clinical clearance...
Clinical trial approval / initiation
Hengrui Pharmaceuticals Receives NMPA Clearance for Phase II Trial of SHR-4849, SHR-8068, and Adebrelimab in Advanced Solid Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received regulatory clearance...
CSPC Pharmaceutical Group Gains NMPA Approval for SYH2068 siRNA Clinical Trials
China-based CSPC Pharmaceutical Group Ltd. (HKG: 1093) has obtained approval from China’s National Medical Products...
Keymed Biosciences Gains NMPA Approval for Phase I/II Study of CM518D1
China-based Keymed Biosciences Inc. (HKG: 2162) announced that it has received approval from the National...
Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China
China-based Hefei Lifeon Pharmaceutical Co., Ltd (SHE: 003020) announced that it has received clinical trial...
Fujian Cosunter Gains NMPA Clearance for Phase II HBV Study of GST-HG131 and GST-HG141
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) announced that it has received clearance from...
Anhui Anke’s Allogeneic CAR-T Therapy UTAA09 Approved for r/r B-ALL Trials
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that its joint venture with...
Juventas Cell Therapy’s CNCT 19 Gains NMPA Approval for Refractory Lupus Nephritis
China-based Juventas Cell Therapy Ltd announced that its chimeric antigen receptor (CAR)-T cell therapy, inaticabtagene...
GenFleet’s KRAS G12D Inhibitor GFH375/VS-7375 Gains FDA Trial Approval
Shanghai-based biotech GenFleet Therapeutics announced that its GFH375/VS-7375, an oral KRAS G12D inhibitor co-developed with...
Doer Biologics Begins Phase II Study of DR10624 for Steatotic Liver Disease
China-based Zhejiang Doer Biologics Co., Ltd has announced the first patient dosing in a Phase...
CSPC Gains NMPA Approval for Phase III Trial of Prusogliptin/Metformin FDC
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has secured approval from the National Medical Products...
CSPC Pharmaceutical Gains FDA IND Clearance for JMT203 in Cancer Cachexia
China-based CSPC Pharmaceutical Group Limited (HKG: 1093) has obtained Investigational New Drug (IND) clearance from...
Biokin Receives NMPA Approval for CD33 ADC in AML Trial
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has received approval...
iMBIORAY Gains NMPA Approval for Phase IITrial of IBR854 in Advanced RCC
Hangzhou-based cancer immunotherapy specialist iMBIORAY has received approval from China’s National Medical Products Administration (NMPA)...
Bio-Thera Solutions Gains NMPA Clinical Approval for BAT7111 in Advanced Solid Tumors
China-based Bio-Thera Solutions Inc. (SHA: 688177) has announced that it has received clinical approval from...
Gan & Lee’s GZR102 Receives NMPA Clinical Trial Clearance for Type 2 Diabetes
China’s Gan & Lee Pharmaceuticals (SHA: 603087) announced that it has received clinical trial clearance...
Hengrui Gains NMPA Approval for Phase III Study of SHR-8068 in PD-L1 Negative NSCLC
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received approval from the National Medical...
Kelun-Biotech Gains FDA Clearance for Phase I Trial of ADC SKB518
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that it has received clearance from the...
Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871
Shanghai-based Rona Therapeutics Inc., a developer of siRNA medicines, has announced that it has received...
Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101
China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical...